Early Breast CancerPhase 1NCT02738970
A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)
A Phase 1 study testing Trastuzumab and Pertuzumab in people with Early Breast Cancer, run by Hoffmann-La Roche at 2 sites in New Zealand.
Trial summary
This study involves a two-part design. Part 1 is designed to determine the optimal dose of subcutaneous (SC) Perjeta, injected alone or mixed with Herceptin, that results in comparable exposure to intravenous (IV) Perjeta. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Early Breast Cancer
- What is being tested?
- Trastuzumab and Pertuzumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 88 participants
- Where
- 2 sitesNew Zealand
- Study dates
- 23 Jun 2016to 31 May 2018
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Part 1: Healthy male volunteers 18 to 45 years of age
- Part 1: Left ventricular ejection fraction (LVEF) at least 55 percent (%)
- Part 1: Body mass index (BMI) 18 to 32 kilograms per meter-squared (kg/m^2)
- Part 1: Normal, intact skin without tattoos or lesions in the injection area
- Part 2: Females at least 18 years of age
- Part 2: Eastern Cooperative Oncology Group (ECOG) performance status of 0
Show all 9Show fewer
- Part 2: Previously treated, non-metastatic carcinoma of the breast
- Part 2: Baseline LVEF at least 55%
- Part 2: Negative pregnancy test and use of adequate contraceptive measures among women of childbearing potential
Who cannot join
- Part 1: Positive urine test for drugs of abuse
- Part 1: History of exposure or active viral infection of Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
- Part 1: Cardiac disease including hypertension or hypotension
- Part 1: Lower extremity edema
- Part 1: Any clinically relevant history of systemic disease
- Part 1: History of breast cancer
Show all 16Show fewer
- Part 1: Chronic corticosteroid use
- Part 1: Receipt of IV antibiotics within 7 days prior to enrollment
- Part 2: Concurrent malignancy requiring therapy that may interfere with pharmacokinetic investigations, or history of other malignancy within 5 years prior to Screening
- Part 2: Significant cumulative exposure to anthracyclines
- Part 2: Serious cardiac disease including uncontrolled hypertension
- Part 2: Poor hematologic, renal, or hepatic function
- Part 2: Pregnant or lactating women
- Part 2: History of exposure or active viral infection of Hepatitis B, hepatitis C, or HIV
- Part 2: Chronic corticosteroid use
- Part 2: Receipt of IV antibiotics within 7 days prior to enrollment
Trial locations and contacts
2 sites in 1 country.
New Zealand2 sites
Auckland Clinical Studies
Auckland, 1142
Christchurch Clinical Studies Trust
Christchurch, 8011
About this study
Official title: A Phase I, Open-Label, Two-Part, Multicenter Perjeta® Subcutaneous Dose-Finding Study in Combination With Herceptin® in Healthy Male Volunteers and Female Patients With Early Breast Cancer
This study involves a two-part design. Part 1 is designed to determine the optimal dose of subcutaneous (SC) Perjeta, injected alone or mixed with Herceptin, that results in comparable exposure to intravenous (IV) Perjeta. Exposure between SC Perjeta and IV Perjeta will be compared using a compilation of pharmacokinetic (PK) parameters such as area under the concentration-time curve (AUC), maximum serum concentration (Cmax), time of maximum concentration (Tmax), and serum trough concentration (Ctrough). Part 2 is designed to confirm the dosing regimen in women with EBC on the basis of safety, tolerability, and PK assessments.
- Conditions
- Early Breast Cancer
- Being tested
- Trastuzumab, Pertuzumab
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TrastuzumabDrug
Also called Herceptin, RO0452317
Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
PertuzumabDrug
Also called Perjeta, RO4368451
Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
| Study group | Role | What they receive |
|---|---|---|
| Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV | Active comparator | Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV. Receives: Drug: Pertuzumab |
| Part 1-Cohort 2: Pertuzumab 400 mg SC | Experimental | Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC. Receives: Drug: Pertuzumab |
| Part 1-Cohort 3: Pertuzumab 600 mg SC | Experimental | Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC. Receives: Drug: Pertuzumab |
| Part 1-Cohort 4: Pertuzumab 1200 mg SC | Experimental | Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC. Receives: Drug: Pertuzumab |
| Part 1-Cohort 5: Trastuzumab 600 mg SC | Active comparator | Part 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC. Receives: Drug: Trastuzumab |
| Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC | Experimental | Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC. Receives: Drug: Trastuzumab; Drug: Pertuzumab |
| Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC | Experimental | Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC. Receives: Drug: Trastuzumab; Drug: Pertuzumab |
| Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC | Experimental | Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient. Receives: Drug: Trastuzumab; Drug: Pertuzumab |
| Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC | Experimental | Part 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1. Receives: Drug: Trastuzumab; Drug: Pertuzumab |
| Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC | Experimental | Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1. Receives: Drug: Trastuzumab; Drug: Pertuzumab |
| Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC | Experimental | Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1. Receives: Drug: Trastuzumab; Drug: Pertuzumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area Under the Concentration from Time Zero to Time Infinity (AUC0-inf) of Pertuzumab SC
Measured: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)
Maximum Serum Concentration (Cmax) of Pertuzumab SC
Measured: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)
Time to Reach Cmax (Tmax) of Pertuzumab SC
Measured: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)
Minimum Serum Concentration (Cmin) of Pertuzumab SC
Measured: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)
AUC0-inf of Pertuzumab IV
Measured: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)
Cmax of Pertuzumab IV
Measured: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)
Tmax of Pertuzumab IV
Measured: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)
Cmin of Pertuzumab IV
Measured: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)
Secondary outcomes (4)
Percentage of Participants with Adverse Events
Measured: Baseline up to approximately 24 months
Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Pertuzumab
Measured: Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 24 months overall)
Percentage of Participants with ATAs to Trastuzumab
Measured: Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 24 months overall)
Percentage of Participants with ATAs to rHuPH20
Measured: Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 24 months overall)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2016 (estimated)
- Study start23 Jun 2016
- Primary completion31 May 2018
- Study completion31 May 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Early Breast CancerStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 88 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02738970
- Sponsor's protocol ID
- BO30185
- Status last verified
- Jun 2018
- First submitted
- 29 Mar 2016
- Last updated
- 12 Jun 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Kirschbrown WP, Wynne C, Kagedal M, Wada R, Li H, Wang B, Nijem I, Badovinac Crnjevic T, Gasser H, Heeson S, Eng-Wong J, Garg A. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study. J Clin Pharmacol. 2019 May;59(5):702-716. doi: 10.1002/jcph.1362. Epub 2018 Dec 19.
PubMed 30570763
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Open-Label, Two-Part, Multicenter Perjeta® Subcutaneous Dose-Finding Study in Combination With Herceptin® in Healthy Male Volunteers and Female Patients With Early Breast Cancer
- ClinicalTrials.gov ID
- NCT02738970
- Acronym / sponsor ID
- BO30185
- Conditions
- Early Breast Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 88 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 23 Jun 2016 (actual)
- Primary completion
- 31 May 2018 (actual)
- Study completion
- 31 May 2018 (actual)
- First posted
- 14 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study involves a two-part design. Part 1 is designed to determine the optimal dose of subcutaneous (SC) Perjeta, injected alone or mixed with Herceptin, that results in comparable exposure to intravenous (IV) Perjeta. Exposure between SC Perjeta and IV Perjeta will be compared using a compilation of pharmacokinetic (PK) parameters such as area under the concentration-time curve (AUC), maximum serum concentration (Cmax), time of maximum concentration (Tmax), and serum trough concentration (Ctrough). Part 2 is designed to confirm the dosing regimen in women with EBC on the basis of safety, tolerability, and PK assessments.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 11
| Arm | Type | Receives |
|---|---|---|
| Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV | Active comparator | Drug: PertuzumabPart 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV. |
| Part 1-Cohort 2: Pertuzumab 400 mg SC | Experimental | Drug: PertuzumabPart 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC. |
| Part 1-Cohort 3: Pertuzumab 600 mg SC | Experimental | Drug: PertuzumabPart 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC. |
| Part 1-Cohort 4: Pertuzumab 1200 mg SC | Experimental | Drug: PertuzumabPart 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC. |
| Part 1-Cohort 5: Trastuzumab 600 mg SC | Active comparator | Drug: TrastuzumabPart 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC. |
| Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC | Experimental | Drug: Trastuzumab, Drug: PertuzumabPart 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC. |
| Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC | Experimental | Drug: Trastuzumab, Drug: PertuzumabPart 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC. |
| Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC | Experimental | Drug: Trastuzumab, Drug: PertuzumabPart 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient. |
| Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC | Experimental | Drug: Trastuzumab, Drug: PertuzumabPart 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1. |
| Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC | Experimental | Drug: Trastuzumab, Drug: PertuzumabPart 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1. |
| Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC | Experimental | Drug: Trastuzumab, Drug: PertuzumabPart 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Part 1: Healthy male volunteers 18 to 45 years of age
- Part 1: Left ventricular ejection fraction (LVEF) at least 55 percent (%)
- Part 1: Body mass index (BMI) 18 to 32 kilograms per meter-squared (kg/m^2)
- Part 1: Normal, intact skin without tattoos or lesions in the injection area
- Part 2: Females at least 18 years of age
Key exclusion criteria (16 listed)
- Part 1: Positive urine test for drugs of abuse
- Part 1: History of exposure or active viral infection of Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
- Part 1: Cardiac disease including hypertension or hypotension
- Part 1: Lower extremity edema
- Part 1: Any clinically relevant history of systemic disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TrastuzumabAlso: Herceptin, RO0452317Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab. | Drug | Part 1-Cohort 5: Trastuzumab 600 mg SC, Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC, Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC, Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC, Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC, Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC, Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC |
| PertuzumabAlso: Perjeta, RO4368451Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg. | Drug | Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV, Part 1-Cohort 2: Pertuzumab 400 mg SC, Part 1-Cohort 3: Pertuzumab 600 mg SC, Part 1-Cohort 4: Pertuzumab 1200 mg SC, Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC, Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC, Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC, Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC, Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC, Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC |
Primary outcome
Area Under the Concentration from Time Zero to Time Infinity (AUC0-inf) of Pertuzumab SC
Time frame: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)
Maximum Serum Concentration (Cmax) of Pertuzumab SC
Time frame: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)
Time to Reach Cmax (Tmax) of Pertuzumab SC
Time frame: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)
Minimum Serum Concentration (Cmin) of Pertuzumab SC
Time frame: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)
AUC0-inf of Pertuzumab IV
Time frame: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)
Cmax of Pertuzumab IV
Time frame: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)
Tmax of Pertuzumab IV
Time frame: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)
Cmin of Pertuzumab IV
Time frame: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)
4 secondary outcomes
Percentage of Participants with Adverse Events
Time frame: Baseline up to approximately 24 months
Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Pertuzumab
Time frame: Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 24 months overall)
Percentage of Participants with ATAs to Trastuzumab
Time frame: Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 24 months overall)
Percentage of Participants with ATAs to rHuPH20
Time frame: Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 24 months overall)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2018.
- Derived from this study: PubMed 30570763Kirschbrown WP, Wynne C, Kagedal M, Wada R, Li H, Wang B, Nijem I, Badovinac Crnjevic T, Gasser H, Heeson S, Eng-Wong J, Garg A. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study. J Clin Pharmacol. 2019 May;59(5):702-716. doi: 10.1002/jcph.1362. Epub 2018 Dec 19.
Related trials for Early Breast Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingObservational study
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
HR+/HER2- Early Breast Cancer
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
RecruitingObservational study
A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization
Early-stage HER2+ Breast Cancer
RecruitingPhase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms, Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Trastuzumab and Pertuzumab in people with Early Breast Cancer, run by Hoffmann-La Roche at 2 sites in New Zealand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area Under the Concentration from Time Zero to Time Infinity (AUC0-inf) of Pertuzumab SC (time frame: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02738970, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2018.